Sigrid Therapeutics has published its shareholder report for the first half of 2026. Sales rose 53 per cent compared with the same period last year, the clinical SHINE study was published in the Lancet family's eClinicalMedicine and CE marking remains on schedule. Here are the key points.
Sales, Jan–Jun
vs H1 2025
Monthly average
May–June vs April 2026
The SHINE study
participants · 3 countries
Sales up 53 per cent
Carb Fence™ was launched in the US during the period – one of the company's most important commercial milestones to date. A Starter Pack was introduced to lower the threshold for first-time buyers. Customer acquisition cost fell and early conversion to subscription exceeded initial expectations. The agreement with Fullscript also provides access to more than 125,000 healthcare providers in the US.
- Sales January–June: +53% compared with the same period in 2025
- Monthly average in May and June: +34% compared with April 2026
| Direct to consumer, US | 57% |
| Direct to consumer, Sweden | 21% |
| Wholesale, Sweden | 15% |
| Wholesale, US | 7% |
The SHINE study published in the Lancet family
SHINE was published in the second quarter in eClinicalMedicine, part of The Lancet Discovery Science. The study is randomised, double-blind and placebo-controlled with 318 participants at 27 clinics in three European countries – the most extensive clinical evaluation of SiPore® to date. The publication provides an independent, peer-reviewed reference point to rely on in the regulatory work and in discussions with potential partners.
CE marking is on schedule
The technical file of more than 400 documents has been reviewed by the notified body Intertek, with no objections in principle in the first round of feedback. The company states that the process is on track: submission before 30 June 2026, CE marking in February–March 2027 and claims for blood sugar and weight control.
The second half of the year
Manufacturing is now in place in both Europe and the US, production economics have improved and the next generation of SiPore® material is under development. Partner dialogues broadened during the quarter to more geographies and areas of application. The company's priorities for the rest of the year:
- CE marking via the MDR programme
- Commercial growth for Carb Fence™ in the US
- A faster pace in the healthcare provider channel
- Continued partner dialogues
- Further development of the SiPore® platform
Source: Sigrid Therapeutics, shareholder report for the first half of 2026 (January–June), published in July 2026.
